New cancer drug DT-9081 tested in early trial – but study stopped early

NCT ID NCT05582850

Terminated Disease control Sponsor: Domain Therapeutics SA Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested an oral drug called DT-9081 in 29 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects. The study was terminated early, so full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DT-9081 (an oral drug)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors who have no other options.
What could go wrong: This is a very early Phase 1 trial, so the drug may not work or may have serious side effects. The trial was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR, ADULT

Contacts and locations

Locations

Institut Claudius Regaud

Toulouse, France
Institut Curie

Paris, France
Institut Jules Bordet

Anderlecht, Belgium
Université Catholique de Louvain

Leuven, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.